期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
吡格列酮二甲双胍复方制剂临床应用专家建议 被引量:1
1
作者 朱大龙 母义明 +12 位作者 翁建平 郭立新 李小英 肖新华 陈丽 孙子林 时立新 余学锋 赖晓阳 章秋 马建华 曾龙驿 叶建平 《药品评价》 CAS 2018年第5期14-19,28,共7页
不同作用机制的口服降糖药联合治疗2型糖尿病在临床应用中已十分广泛,其中二甲双胍联合吡格列酮是中华医学会糖尿病学分会、美国糖尿病协会等国内外指南推荐的首选治疗方案之一。吡格列酮二甲双胍片作为二者的固定复方制剂,具有经济方... 不同作用机制的口服降糖药联合治疗2型糖尿病在临床应用中已十分广泛,其中二甲双胍联合吡格列酮是中华医学会糖尿病学分会、美国糖尿病协会等国内外指南推荐的首选治疗方案之一。吡格列酮二甲双胍片作为二者的固定复方制剂,具有经济方便的优点,同时提高了患者的用药依从性。临床应用时可根据患者的具体情况单独使用吡格列酮二甲双胍片,或与其他多种口服降糖药联合用药。为提高临床医生对此类单片复方制剂的认识,促进基层治疗的合理用药,根据现有的循证证据,制定了《吡格列酮二甲双胍复方制剂临床应用专家建议》,分别从临床地位、作用机制、疗效、安全、推荐人群和特殊人群等方面进行阐述。 展开更多
关键词 吡格列酮二甲双胍片 吡格列酮 二甲双胍 临床应用 专家建议
下载PDF
Inadequate glycaemic control and antidiabetic therapy among inpatients with type 2 diabetes in Guangdong Province of China 被引量:5
2
作者 BI Yan YAN Jin-hua +13 位作者 LIAO Zhi-hong LI Yan-bing zeng long-yi TANG Kuan-xiao XUE Yao-ming YANG Hua-zhang LI Lu CAI De-hong WU Ge ZHANG Fan LIN Shao-da XIAO Zheng-hua ZHU Da-long WENG Jian-ping 《Chinese Medical Journal》 SCIE CAS CSCD 2008年第8期677-681,共5页
Background Diabetes mellitus has become epidemic in recent years in China. We investigated the prevalence of hyperglycaemia and inadequate glycaemic control among type 2 diabetic inpatients from ten university teachin... Background Diabetes mellitus has become epidemic in recent years in China. We investigated the prevalence of hyperglycaemia and inadequate glycaemic control among type 2 diabetic inpatients from ten university teaching hospitals in Guangdong Province, China. Methods Inadequate glycaemic control in diabetic patients was defined as HbA1c 〉 6.5%. Therapeutic regimens included no-intervention, lifestyle only, oral antiglycemic agents (OA), insulin plus OA (insulin+OA), or insulin only. Antidiabetic managements included monotherapy, double therapy, triple or quadruple therapy. Results Among 493 diabetic inpatients with known history, 75% had HbA1c ≥ 6.5%. inadequate glucose control rates were more frequently seen in patients on insulin+OA regimen (97%) ,than on OA regimen (71%) (P 〈0.001), and more frequent in patients on combination therapy (81%-96%) than monotherapy (7,5%) (P 〈0.0,5). Patients on insulin differed significantly from patients on OA by mean HbA1c, glycemic control rate, diabetes duration, microvascular complications, and BMI (P 〈0.01). Conclusions This study showed that glycaemic control of type 2 diabetic patients deteriorated for patients who received insulin and initiation time of insulin was usually delayed, it is up to clinicians to move from the traditional stepwise therapy to a more active and early combination antidiabetic therapy to provide better glucose control. 展开更多
关键词 type 2 diabetes INPATIENT glycaemic control antidiabetic therapy
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部